Mayne Pharma Group Limited

Informe acción ASX:MYX

Capitalización de mercado: AU$565.6m

Salud financiera de hoja de balance de Mayne Pharma Group

Salud financiera controles de criterios 6/6

Mayne Pharma Group tiene un patrimonio de los accionistas total de A$547.8M y una deuda total de A$30.0M, lo que sitúa su ratio deuda-patrimonio en 5.5%. Sus activos y pasivos totales son A$1.2B y A$604.9M respectivamente.

Información clave

5.5%

Ratio deuda-patrimonio

AU$30.02m

Deuda

Ratio de cobertura de interesesn/a
EfectivoAU$154.81m
PatrimonioAU$547.77m
Total pasivoAU$604.88m
Activos totalesAU$1.15b

Actualizaciones recientes sobre salud financiera

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12
Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16
We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10
Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17
Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22
Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01
How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08
What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18
Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27
Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09
Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$475.3M) de MYX superan a sus pasivos a corto plazo (A$295.7M).

Pasivo a largo plazo: Los activos a corto plazo de MYX (A$475.3M) superan a sus pasivos a largo plazo (A$309.2M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: MYX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de MYX ha pasado de 30.4% a 5.5% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MYX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: MYX dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 48.2% cada año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target